Komori
Share Issuance and Disposal4553TOWA PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding Completion of Payment for the Series 1 Class A Preferred Shares through a Third-Party Allotment and the Effectiveness of the Reduction in the Amounts of Capital Stock and Capital Reserve

Payment for 10,000 Class A Preferred Shares through a third-party allotment was completed, raising ¥10 billion. At the same time, the increased stated capital and capital reserve were each reduced by ¥5 billion and transferred to other capital reserve.

Worth reading
64In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
10000000000
¥
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of Series 1 Class A Preferred Shares through a third-party allotment

Who receives how much10,000Shares

10,000 Class A Preferred Shares

Development Bank of Japan, Inc., 10,000 shares

The lower thin line represents the existing number of shares to which these shares will be added.

¥1,000,000 per share
Total issue value

¥10,000,000,000

Amount of funds to be raised
Total payment amount: ¥10,000,000,000; estimated net proceeds: Not disclosed
Payment date
31 July 2026
Procedures under the Corporate Code of Conduct
Approved at the 70th Annual General Meeting of Shareholders held on 24 June 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of Series 1 Class A Preferred Shares through a third-party allotment
Number of shares to be issued or disposed of10,000 Class A Preferred Shares
Issue price and disposal price¥1,000,000 per share
Total issue value¥10,000,000,000
Amount of funds to be raisedTotal payment amount: ¥10,000,000,000; estimated net proceeds: Not disclosed
Payment date31 July 2026
Intended allotteeDevelopment Bank of Japan, Inc., 10,000 shares
Procedures under the Corporate Code of ConductApproved at the 70th Annual General Meeting of Shareholders held on 24 June 2026
Items this document does not state (20)
Estimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The entire amount of stated capital and capital reserve increased in connection with the issuance of Series 1 Class A Preferred Shares was reduced and transferred to other capital reserve.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Completion of Payment for the Series 1 Class A Preferred Shares through a Third-Party Allotment and the Effectiveness of the Reduction in the Amounts of Capital Stock and Capital Reserve | TOWA PHARMACEUTICAL CO.,LTD. (4553) timely disclosure | Komori